SPACs for the Long-Term with True Wind Capital’s Scott Wagner & Tom Hegge

by | Oct 6, 2021

True Wind Capital’s track record as a SPAC sponsor is about as good as it gets. Open Lending Corp (LPRO) is an absolute rock star deSPAC up over 240% since IPO, Rover (ROVR) is up 30% since IPO, and there is more on the way from them with Bilander Acquisition (TWCB) looking for a deal and 3 more in the queue to IPO.

Boardroom Alpha’s David Drapkin is joined by True Wind Capital’s Scott Wagner and Tom Hegge. Listeners will remember Scott as the ex-CEO of GoDaddy and  Tom is a long-time public market investor with private equity roots.

Listen in as the three discuss the SPAC market, what makes True Wind special, and how a SPAC sponsor can successfully build a track record of taking companies public and driving return for all stakeholders.

Learn more about True Wind Capital: https://www.truewindcapital.com/

<a href="https://www.boardroomalpha.com/author/draps/" target="_self">David Drapkin</a>

David Drapkin

Spent his formative years at Goldman Sachs and now embraces the start-up life in NYC. A long suffering Oakland (Las Vegas) Raiders fan and graduate of the Wharton School at the University of Pennsylvania. Semi-professional go-kart racer waiting for his shot.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

Learn More

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Learn More

Monthly SPAC Review

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SPAC Research & Analysis

MSP Recovery Debuts Tomorrow

May 23, 2022

Medicare and Medicaid secondary payer reimbursement recovery specialist MSP Recovery (MSPR) begins trading tomorrow. Extension for TINV/Grindr. And the rest of the day’s news in SPACs.

Comera Life Sciences Debuts in the Red

May 20, 2022

Comera Life Sciences (CMRA), the maker of self-injectible biologics, deSPAC’d today, closing down 9%. An updated look at deSPAC count and redemption rates. And the rest of the day’s news in SPACs.

Starting the Week with 2 DAs

May 16, 2022

Starting the week off with 2 DAs– oil & gas and battery tech. And the rest of the day’s news in SPACs.

Know Who Drives Return Podcast

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.